Company / Gross Profit
Jazz Pharmaceuticals Gross Profit History
FY2016-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$469.8M
FY2019
5-year range
-
FY2016-FY2019
Trend
+15.5%
vs FY2018
Sector context
#15 of 29
Health Care
What the data says
At $470M, Jazz Pharmaceuticals's gross profit ranks #15 of 29 in the Health Care sector. Gross Profit has increased for 3 consecutive years, from $310M in FY2016 to $470M in FY2019.
Based on SEC 10-K filings.
$470M in FY2019 with a 3-year CAGR of +14.8%.
Improved from $349M to $470M over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- +14.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#15 of 29 in Health CareTop 52% of 29This company $469.8M Sector average $3.5B
▼
-86.4% below sector average
Key checks
Key Insights
- Jazz Pharmaceuticals's gross profit has grown for 3 consecutive years.
- 3-year CAGR of +14.8%, indicating consistent growth.
- In FY2019, gross profit increased 15.5% year-over-year.
- Ranks #15 out of 29 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | $469.8M | +15.5% |
| FY2018 | $406.9M | +16.7% |
| FY2017 | $348.6M | +12.3% |
| FY2016 | $310.5M | +11.4% |
As of FY2019 · SEC 10-K · Updated Jun 30, 2026